Thursday, September 23

Brussels approves the purchase of 100 million Novavax vaccines


The EC buys vaccines from Novavax.

The EC buys vaccines from Novavax.
EFE

The European Commission (EC) approved this Wednesday a advanced purchase agreement with Novavax to acquire 100 million doses of the vaccine against the coronavirus of that pharmaceutical company, with the option of receiving another 100 million, according to the community Executive itself.

According to Brussels in a statement, it will be possible with this contract to access a potential vaccine against Covid-19 in the fourth quarter of 2021 and in 2022.

“Under this contract, Member States will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for an additional 100 million doses during 2021, 2022 and 2023, once (the injection) is reviewed and approved by the European Medicines Agency (EMA) as safe and effective, “explained the EC.

Member States will also be able to donate doses to low- and middle-income countries or deliver them to other European countries.

Novavax is a biotech company developing next-generation vaccines for serious infectious diseases, and the EMA is already analyzing its coronavirus vaccine data in real time.

Brussels added that has decided to support this injection based on “a solid scientific evaluation, the technology used, the company’s experience in vaccine development and its production capacity to supply the entire EU. ”

The EC has also signed contracts for Covid vaccines with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Moderna and has held discussions with the same objective with Valneva.

The step taken this Wednesday is essential for “ensure that Europe is well prepared to face the pandemic”, indicated the EC.

The president of the European Commission, Ursula von der Leyen, said in a statement that as new variants of the coronavirus spread in Europe and around the world, “this new contract with a company that is already successfully testing its vaccine against these variants is an additional safeguard for the protection of our population. ”

It further strengthens our broad portfolio of vaccines, for the benefit of Europeans and our partners around the world“, he indicated.

“The new agreement with Novavax expands our portfolio of vaccines to include a new one based on proteins,” said the European Health Minister, Stella Kyriakides, who recalled that the EU is “closer to the goal of 70% of citizens fully vaccinated by late summer. ”

The European Commission presented on June 17 a European strategy to accelerate the development, manufacture and deployment of effective and safe vaccines against Covid-19.

In view of the SARS-CoV-2 variants, the Commission and Member States are negotiating with companies already in the EU vaccine portfolio new agreements that will allow for the purchase of rapidly adapted vaccines in sufficient quantities to strengthen and prolong immunity .


www.informacion.es

Leave a Reply

Your email address will not be published. Required fields are marked *

Share